Ivermectin 1% cream for rosacea
Recommended Citation
Gupta G, Daigle D, Gupta AK, Gold LS. Ivermectin 1% cream for rosacea. Skin therapy letter 2015; 20(4):9-11.
Document Type
Article
Publication Date
7-1-2015
Publication Title
Skin therapy letter
Abstract
The etiology of papulopustular rosacea (PPR) is not well understood yet appears to involve both the innate and adaptive immune response in addition to possible infestation with Demodex mites. Current treatments for PPR consist mainly of antibiotics. Ivermectin cream 1%, a new topical treatment for PPR, possesses both anti-inflammatory and anti-parasitic properties. After 12 weeks of treatment, subjects treated with ivermectin cream 1% had significantly greater reductions in PPR symptoms and enhanced diseaserelated quality of life improvements compared to subjects who received vehicle. Furthermore, PPR symptoms continued to improve with prolonged treatment (40 weeks). Ivermectin cream 1% offers a multi-pronged approach to combat the complex pathophysiology of rosacea.
Medical Subject Headings
Administration, Topical; Anti-Infective Agents; Antiparasitic Agents; Clinical Trials, Phase III as Topic; Dermatologic Agents; Dicarboxylic Acids; Female; Humans; Ivermectin; Male; Metronidazole; Middle Aged; Rosacea; Skin Cream
PubMed ID
26382711
Volume
20
Issue
4
First Page
9
Last Page
11
